(Q38303633)

1 September 2017

Gene expression profiles reveal homeostatic dynamics during interferon-beta therapy in multiple sclerosis (English)

1 reference

1 September 2017

Marco Alfò

9

1 reference

ORCID Public Data File 2021

author name string

Viviana Annibali

1

1 reference

1 September 2017

Simone Di Giovanni

2

1 reference

1 September 2017

Stefania Cannoni

3

1 reference

1 September 2017

Elisabetta Giugni

4

1 reference

1 September 2017

Roberto Bomprezzi

5

1 reference

1 September 2017

Carlo Mattei

6

1 reference

1 September 2017

Abdel Elkahloun

7

1 reference

1 September 2017

Eliana Marina Coccia

8

1 reference

1 September 2017

Francesco Orzi

10

1 reference

1 September 2017

Giovanni Ristori

11

1 reference

1 September 2017

Marco Salvetti

12

1 reference

1 September 2017

1 February 2007

1 reference

1 September 2017

1 reference

1 September 2017

40

1 reference

1 September 2017

1

1 reference

1 September 2017

16-22

1 reference

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

1 September 2017

1 reference

https://api.crossref.org/works/10.1080%2F08916930601135241

Microarray analysis identifies interferon beta-regulated genes in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930601135241

Genomic effects of IFN-beta in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930601135241

Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930601135241

Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930601135241

Beneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930601135241

10.1080/08916930601135241

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference